Reproductive decision-making and the utilization of preimplantation genetic testing among individuals with inherited aortic or vascular disease

被引:4
作者
Patton, Kaleigh [1 ,2 ]
Wong, Eugene K. [3 ,4 ]
Cirino, Allison L. [1 ,5 ]
Dobson, Lori J. [1 ,6 ]
Harris, Stephanie [3 ]
机构
[1] MGH Inst Hlth Profess, Genet Counseling Program, Boston, MA 02129 USA
[2] Dana Farber Canc Inst, Div Canc Genet & Prevent, Boston, MA USA
[3] Massachusetts Gen Hosp, Cardiovasc Genet Program, Cardiol Div, Boston, MA USA
[4] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA USA
[5] Brigham & Womens Hosp, Cardiovasc Div, Boston, MA USA
[6] Brigham & Womens Hosp, Ctr Fetal Med & Reprod Genet, Boston, MA USA
关键词
aortic disease; decision-making; lived experience; preimplantation genetic testing (PGT-M); HEREDITARY BREAST; MARFANS-SYNDROME; DIAGNOSIS; PREGNANCY; COUPLES; EXPERIENCES; KNOWLEDGE; ATTITUDES;
D O I
10.1002/jgc4.1759
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Preimplantation genetic testing for monogenic disorders (PGT-M) is a reproductive technology used in conjunction with in-vitro fertilization (IVF) to reduce the risk of passing on a known genetic condition from parent to child. There is limited research describing the experience and emotional impact of PGT-M among individuals with inherited aortic or vascular disease (IAVD). Our qualitative study aims to explore the factors that influence reproductive decision-making and the uptake of PGT-M within this population. Individuals diagnosed with IAVD who have considered PGT-M, and/or their reproductive partner, were recruited using internal clinical databases and advocacy organizations. Virtual semi-structured interviews were conducted using an interview guide that included questions related to participants' lived experience of their condition, risk perception, reproductive history, familiarity with PGT-M/IVF, and financial/psychosocial considerations. A total of 17 interviews were completed (13 affected individuals, 4 unaffected partners) and analyzed using thematic analysis. Emergent themes included: (1) the lived experience and perceived severity of disease; (2) need for comprehensive, balanced, and timely information; (3) and impact of personal values and circumstances. When discussing the impact of lived experience on reproductive decision-making, participants identified the physical and emotional impact of disease and variability of disease as factors influencing the uptake of PGT-M. Many described PGT-M as the only reproductive option presented to them by providers. Even so, participants expressed gaps in their understanding of PGT-M, particularly regarding cost/insurance coverage and the experience of IVF. Finally, participants recognized that the decision to pursue PGT-M primarily requires introspection and evaluation of one's values, but that cost remains a significant consideration. The findings from our study highlight the complexity of reproductive decision-making for individuals with IAVD and provide insight into their psychological and informational needs when engaging in this process. Providers can use these findings to tailor their discussions about reproductive decision-making with this patient cohort.
引用
收藏
页码:592 / 604
页数:13
相关论文
共 30 条
  • [2] Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes
    Brandt, Amanda C.
    Tschirgi, Matthew L.
    Ready, Kaylene J.
    Sun, Charlotte
    Darilek, Sandra
    Hecht, Jacqueline
    Arun, Banu K.
    Lu, Karen H.
    [J]. FAMILIAL CANCER, 2010, 9 (03) : 479 - 487
  • [3] Factors influencing patients' decision-making about preimplantation genetic testing for monogenic disorders
    Cheng, Lin
    Meiser, Bettina
    Kirk, Edwin
    Kennedy, Debra
    Barlow-Stewart, Kristine
    Kaur, Rajneesh
    [J]. HUMAN REPRODUCTION, 2022, 37 (11) : 2599 - 2610
  • [4] Clarke V., 2014, SAGE HDB QUALITATIVE, P1947, DOI [10.1007/978-1-4614-5583-7_311, DOI 10.1037/13620-004, 10.1080/17439760.2016.1262613, DOI 10.1080/17439760.2016.1262613]
  • [5] What do French patients and geneticists think about prenatal and preimplantation diagnoses in Marfan syndrome?
    Coron, F.
    Rousseau, T.
    Jondeau, G.
    Gautier, E.
    Binquet, C.
    Gouya, L.
    Cusin, V.
    Odent, S.
    Dulac, Y.
    Plauchu, H.
    Collignon, P.
    Delrue, M. -A.
    Leheup, B.
    Joly, L.
    Huet, F.
    Thevenon, J.
    Mace, G.
    Cassini, C.
    Thauvin-Robinet, C.
    Wolf, J. E.
    Hanna, N.
    Sagot, P.
    Boileau, C.
    Faivre, L.
    [J]. PRENATAL DIAGNOSIS, 2012, 32 (13) : 1318 - 1323
  • [6] Marfan syndrome and pregnancy: maternal and neonatal outcomes
    Curry, R. A.
    Gelson, E.
    Swan, L.
    Dob, D.
    Babu-Narayan, S. V.
    Gatzoulis, M. A.
    Steer, P. J.
    Johnson, M. R.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 (05) : 610 - 617
  • [7] Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer
    Derks-Smeets, I. A. P.
    Gietel-Habets, J. J. G.
    Tibben, A.
    Tjan-Heijnen, V. C. G.
    Meijer-Hoogeveen, M.
    Geraedts, J. P. M.
    van Golde, R.
    Gomez-Garcia, E.
    van den Bogaart, E.
    van Hooijdonk, M.
    de Die-Smulders, C. E. M.
    van Osch, L. A. D. M.
    [J]. HUMAN REPRODUCTION, 2014, 29 (05) : 1103 - 1112
  • [8] A Qualitative Inquiry of the Financial Concerns of Couples Opting to Use Preimplantation Genetic Diagnosis to Prevent the Transmission of Known Genetic Disorders
    Drazba, Kathryn T.
    Kelley, Michele A.
    Hershberger, Patricia E.
    [J]. JOURNAL OF GENETIC COUNSELING, 2014, 23 (02) : 202 - 211
  • [9] How do patient perceived determinants influence the decision-making process to accept or decline preimplantation genetic screening?
    Gebhart, Marty Brown
    Hines, Randall S.
    Penman, Alan
    Holland, Aimee Chism
    [J]. FERTILITY AND STERILITY, 2016, 105 (01) : 188 - 193
  • [10] Professionals' knowledge, attitude and referral behaviour of preimplantation genetic diagnosis for hereditary breast and ovarian cancer
    Gietel-Habets, J. J. G.
    de Die-Smulders, C. E. M.
    Tjan-Heijnen, V. C. G.
    Derks-Smeets, I. A. P.
    van Golde, R.
    Gomez-Garcia, E.
    van Osch, L. A. D. M.
    [J]. REPRODUCTIVE BIOMEDICINE ONLINE, 2018, 36 (02) : 137 - 144